Overview

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Status:
Recruiting

Trial end date:
2025-12-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and feasibility of outpatient blinatumomab administration for subjects with Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Blinatumomab